Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis.
Visentini M, Del Padre M, Colantuono S, Yang B, Minafò YA, Antonini S, Carnovale M, De Santis A, Pulsoni A, De Sanctis GM, Gragnani L, Zignego AL, Fiorilli M, Casato M. Visentini M, et al. Among authors: de sanctis gm. Liver Int. 2019 Apr;39(4):628-632. doi: 10.1111/liv.14053. Epub 2019 Feb 15. Liver Int. 2019. PMID: 30690862
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.
Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. Among authors: de sanctis gm. Dig Liver Dis. 2011 Dec;43(12):975-83. doi: 10.1016/j.dld.2011.07.002. Epub 2011 Aug 9. Dig Liver Dis. 2011. PMID: 21831732
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spanò A, Perno CF. Svicher V, et al. Among authors: de sanctis gm. Dig Liver Dis. 2010 Dec;42(12):902-7. doi: 10.1016/j.dld.2010.04.017. Epub 2010 Jun 19. Dig Liver Dis. 2010. PMID: 20621632
A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy.
Angelico M, Cepparulo M, Angelico F, Francioso S, Barlattani A, Di Candilo F, Della Vecchia R, Demelia L, De Sanctis G, Gentile S, Grieco A, Parruti G, Sabusco G, Tarquini L, Tosti A, Zaru S; SMIEC 1 GROUP. Angelico M, et al. Aliment Pharmacol Ther. 2004 Feb 1;19(3):339-47. doi: 10.1111/j.1365-2036.2004.01843.x. Aliment Pharmacol Ther. 2004. PMID: 14984381 Free article. Clinical Trial.
Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.
Cento V, Mirabelli C, Dimonte S, Salpini R, Han Y, Trimoulet P, Bertoli A, Micheli V, Gubertini G, Cappiello G, Spanò A, Longo R, Bernassola M, Mazzotta F, De Sanctis GM, Zhang XX, Verheyen J, D'Arminio Monforte A, Ceccherini-Silberstein F, Perno CF, Svicher V. Cento V, et al. Among authors: de sanctis gm. J Gen Virol. 2013 Jan;94(Pt 1):143-149. doi: 10.1099/vir.0.046524-0. Epub 2012 Oct 10. J Gen Virol. 2013. PMID: 23052389
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.
Cento V, Van Hemert F, Neumann-Fraune M, Mirabelli C, Di Maio VC, Salpini R, Bertoli A, Micheli V, Gubertini G, Romano S, Visca M, De Sanctis GM, Berkhout B, Marino N, Mazzotta F, Cappiello G, Spanò A, Sarrecchia C, Ceccherini-Silberstein F, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V. Cento V, et al. Among authors: de sanctis gm. J Infect. 2013 Oct;67(4):303-12. doi: 10.1016/j.jinf.2013.05.008. Epub 2013 Jun 22. J Infect. 2013. PMID: 23796863
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, Micheli V, Cappiello T, Spanò A, Rizzardini G, De Sanctis GM, Sarrecchia C, Angelico M, Perno CF. Salpini R, et al. Among authors: de sanctis gm. Antiviral Res. 2011 Nov;92(2):382-5. doi: 10.1016/j.antiviral.2011.08.013. Epub 2011 Sep 5. Antiviral Res. 2011. PMID: 21920388
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spanò A, Cappiello G, Perno CF. Svicher V, et al. Among authors: de sanctis gm. J Hepatol. 2009 Mar;50(3):461-70. doi: 10.1016/j.jhep.2008.07.038. Epub 2008 Oct 18. J Hepatol. 2009. PMID: 19041149
24 results